Search

Your search keyword '"Seung, Kwonjune J."' showing total 155 results
Start Over Author "Seung, Kwonjune J."
155 results on '"Seung, Kwonjune J."'

1. Sputum culture reversion in longer treatments with bedaquiline, delamanid, and repurposed drugs for drug-resistant tuberculosis

Author

Kho, Sooyeon, primary, Seung, Kwonjune J., additional, Huerga, Helena, additional, Bastard, Mathieu, additional, Khan, Palwasha Y., additional, Mitnick, Carole D., additional, Rich, Michael L., additional, Islam, Shirajul, additional, Zhizhilashvili, Dali, additional, Yeghiazaryan, Lusine, additional, Nikolenko, Elena Nikolaevna, additional, Zarli, Khin, additional, Adnan, Sana, additional, Salahuddin, Naseem, additional, Ahmed, Saman, additional, Vargas, Zully Haydee Ruíz, additional, Bekele, Amsalu, additional, Shaimerdenova, Aiman, additional, Tamirat, Meseret, additional, Gelin, Alain, additional, Vilbrun, Stalz Charles, additional, Hewison, Catherine, additional, Khan, Uzma, additional, and Franke, Molly, additional

Published
2024
Full Text
View/download PDF

2. Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis

Author

treatment–2017, The Collaborative Group for the Meta-Analysis of Individual Patient Data in MDR-TB, Ahmad, Nafees, Ahuja, Shama D, Akkerman, Onno W, Alffenaar, Jan-Willem C, Anderson, Laura F, Baghaei, Parvaneh, Bang, Didi, Barry, Pennan M, Bastos, Mayara L, Behera, Digamber, Benedetti, Andrea, Bisson, Gregory P, Boeree, Martin J, Bonnet, Maryline, Brode, Sarah K, Brust, James CM, Cai, Ying, Caumes, Eric, Cegielski, J Peter, Centis, Rosella, Chan, Pei-Chun, Chan, Edward D, Chang, Kwok-Chiu, Charles, Macarthur, Cirule, Andra, Dalcolmo, Margareth Pretti, D'Ambrosio, Lia, de Vries, Gerard, Dheda, Keertan, Esmail, Aliasgar, Flood, Jennifer, Fox, Gregory J, Fréchet-Jachym, Mathilde, Fregona, Geisa, Gayoso, Regina, Gegia, Medea, Gler, Maria Tarcela, Gu, Sue, Guglielmetti, Lorenzo, Holtz, Timothy H, Hughes, Jennifer, Isaakidis, Petros, Jarlsberg, Leah, Kempker, Russell R, Keshavjee, Salmaan, Khan, Faiz Ahmad, Kipiani, Maia, Koenig, Serena P, Koh, Won-Jung, Kritski, Afranio, Kuksa, Liga, Kvasnovsky, Charlotte L, Kwak, Nakwon, Lan, Zhiyi, Lange, Christoph, Laniado-Laborín, Rafael, Lee, Myungsun, Leimane, Vaira, Leung, Chi-Chiu, Leung, Eric Chung-Ching, Li, Pei Zhi, Lowenthal, Phil, Maciel, Ethel L, Marks, Suzanne M, Mase, Sundari, Mbuagbaw, Lawrence, Migliori, Giovanni B, Milanov, Vladimir, Miller, Ann C, Mitnick, Carole D, Modongo, Chawangwa, Mohr, Erika, Monedero, Ignacio, Nahid, Payam, Ndjeka, Norbert, O'Donnell, Max R, Padayatchi, Nesri, Palmero, Domingo, Pape, Jean William, Podewils, Laura J, Reynolds, Ian, Riekstina, Vija, Robert, Jérôme, Rodriguez, Maria, Seaworth, Barbara, Seung, Kwonjune J, Schnippel, Kathryn, Shim, Tae Sun, Singla, Rupak, Smith, Sarah E, Sotgiu, Giovanni, Sukhbaatar, Ganzaya, Tabarsi, Payam, Tiberi, Simon, Trajman, Anete, Trieu, Lisa, Udwadia, Zarir F, van der Werf, Tjip S, and Veziris, Nicolas

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Clinical Research, Tuberculosis, Lung, Antimicrobial Resistance, Prevention, Clinical Trials and Supportive Activities, Rare Diseases, Orphan Drug, Evaluation of treatments and therapeutic interventions, 6.1 Pharmaceuticals, Infection, Good Health and Well Being, Amikacin, Antitubercular Agents, Capreomycin, Carbapenems, Clofazimine, Diarylquinolines, Drug Therapy, Combination, Fluoroquinolones, Humans, Kanamycin, Levofloxacin, Linezolid, Moxifloxacin, Recurrence, Treatment Failure, Tuberculosis, Multidrug-Resistant, Tuberculosis, Pulmonary, Collaborative Group for the Meta-Analysis of Individual Patient Data in MDR-TB treatment–2017, Medical and Health Sciences, General & Internal Medicine, Biomedical and clinical sciences, Health sciences
Abstract

BackgroundTreatment outcomes for multidrug-resistant tuberculosis remain poor. We aimed to estimate the association of treatment success and death with the use of individual drugs, and the optimal number and duration of treatment with those drugs in patients with multidrug-resistant tuberculosis.MethodsIn this individual patient data meta-analysis, we searched MEDLINE, Embase, and the Cochrane Library to identify potentially eligible observational and experimental studies published between Jan 1, 2009, and April 30, 2016. We also searched reference lists from all systematic reviews of treatment of multidrug-resistant tuberculosis published since 2009. To be eligible, studies had to report original results, with end of treatment outcomes (treatment completion [success], failure, or relapse) in cohorts of at least 25 adults (aged >18 years). We used anonymised individual patient data from eligible studies, provided by study investigators, regarding clinical characteristics, treatment, and outcomes. Using propensity score-matched generalised mixed effects logistic, or linear regression, we calculated adjusted odds ratios and adjusted risk differences for success or death during treatment, for specific drugs currently used to treat multidrug-resistant tuberculosis, as well as the number of drugs used and treatment duration.FindingsOf 12 030 patients from 25 countries in 50 studies, 7346 (61%) had treatment success, 1017 (8%) had failure or relapse, and 1729 (14%) died. Compared with failure or relapse, treatment success was positively associated with the use of linezolid (adjusted risk difference 0·15, 95% CI 0·11 to 0·18), levofloxacin (0·15, 0·13 to 0·18), carbapenems (0·14, 0·06 to 0·21), moxifloxacin (0·11, 0·08 to 0·14), bedaquiline (0·10, 0·05 to 0·14), and clofazimine (0·06, 0·01 to 0·10). There was a significant association between reduced mortality and use of linezolid (-0·20, -0·23 to -0·16), levofloxacin (-0·06, -0·09 to -0·04), moxifloxacin (-0·07, -0·10 to -0·04), or bedaquiline (-0·14, -0·19 to -0·10). Compared with regimens without any injectable drug, amikacin provided modest benefits, but kanamycin and capreomycin were associated with worse outcomes. The remaining drugs were associated with slight or no improvements in outcomes. Treatment outcomes were significantly worse for most drugs if they were used despite in-vitro resistance. The optimal number of effective drugs seemed to be five in the initial phase, and four in the continuation phase. In these adjusted analyses, heterogeneity, based on a simulated I2 method, was high for approximately half the estimates for specific drugs, although relatively low for number of drugs and durations analyses.InterpretationAlthough inferences are limited by the observational nature of these data, treatment outcomes were significantly better with use of linezolid, later generation fluoroquinolones, bedaquiline, clofazimine, and carbapenems for treatment of multidrug-resistant tuberculosis. These findings emphasise the need for trials to ascertain the optimal combination and duration of these drugs for treatment of this condition.FundingAmerican Thoracic Society, Canadian Institutes of Health Research, US Centers for Disease Control and Prevention, European Respiratory Society, Infectious Diseases Society of America.

Published
2018

4. Effectiveness of a bedaquiline, linezolid, clofazimine "core" for multidrug-resistant tuberculosis

Author

Zeng, Chengbo, primary, Hernan, Miguel A., additional, Trevisi, Letizia, additional, Sauer, Sara, additional, Mitnick, Carole D., additional, Hewison, Catherine, additional, Bastard, Mathieu, additional, Khan, Palwasha, additional, Seung, Kwonjune J., additional, Rich, Michael L., additional, Law, Stephaine, additional, Kikvidze, Marina, additional, Kirakosyan, Ohanna, additional, Miankou, Alexey, additional, Thit, Phone, additional, Mamsa, Shahid, additional, Janmohamed, Aleeza, additional, Melikyan, Nara, additional, Ahmed, Saman, additional, Vargas, Dante, additional, Binegdie, Amsalu Bekele, additional, Temirova, Kulbaram, additional, Oyewusi, Lawrence, additional, Philippe, Kerline, additional, Vilbrun, Stalz C., additional, Khan, Uzma, additional, Huerga, Helena, additional, and Franke, Molly F., additional

Published
2024
Full Text
View/download PDF

5. COVID-19 in Patients with Drug-Resistant Tuberculosis in Lesotho

Author

Andom, Afom T., primary, Asfaw, Meseret, additional, Maama-Maime, Llang Bridget, additional, Kunda, Mikanda, additional, Mpinda, Stephane, additional, Mukherjee, Joia, additional, Ndayizigiye, Melino, additional, Sheyo, Ninza, additional, Zulu, Mosala, additional, Mitnick, Carole D., additional, and Seung, Kwonjune J., additional

Published
2023
Full Text
View/download PDF

6. Pregnancy and Birth Outcomes in Patients With Multidrug-Resistant Tuberculosis Treated With Regimens That Include New and Repurposed Drugs

Author

Lotia Farrukh, Ismat, primary, Lachenal, Nathalie, additional, Adenov, Malik M, additional, Ahmed, Saman, additional, Algozhin, Yerkebulan, additional, Coutisson, Sylvine, additional, Garavito, Epifanio Sánchez, additional, Hewison, Catherine, additional, Holtzman, David, additional, Huerga, Helena, additional, Janmohamed, Aleeza, additional, Khan, Palwasha Y, additional, Jacques, Gamarly Leblanc, additional, Lomtadze, Nino, additional, Melikyan, Nara, additional, Mitnick, Carole D, additional, Mussabekova, Gulnaz, additional, Osso, Elna, additional, Perea, Sara, additional, Putri, Fauziah Asnely, additional, Rashidov, Mahmud, additional, Rich, Michael L, additional, Sakhabutdinova, Yekaterina, additional, Seung, Kwonjune J, additional, Stambekova, Assel, additional, Vásquez, Dante Vargas, additional, Franke, Molly F, additional, and Khan, Uzma, additional

Published
2023
Full Text
View/download PDF

7. List of Contributors

Author

Acosta, Anna M., primary, Acuin, Jose M., additional, Adam, Rodney D., additional, Afroze, Farzana, additional, Ahmed, Nadia, additional, Ahmed, Sabeena, additional, Ahmed, Tahmeed, additional, Ahmed, A.M. Shamsir, additional, Ali, S. Asad, additional, Ali, Ibne K., additional, Alroy, Karen A., additional, Ananthakrishnan, Ashwin N., additional, Ansong, Daniel, additional, Anstead, Gregory M., additional, Appleby, Laura J., additional, Armah, George E., additional, Aronson, Naomi E., additional, Aston, Stephen J., additional, Barnett, Elizabeth D., additional, Bartelt, Luther A., additional, Bates, Imelda, additional, Bausch, Daniel G., additional, Beadling, Charles W., additional, Beeching, Nicholas J., additional, Bennish, Michael L., additional, Bern, Caryn, additional, Bernstein, Wendy B., additional, Bird, Brian H., additional, Bloom, Allyson K., additional, Bodeker, Gerard, additional, Boyer Chammard, Timothée, additional, Bradsher, Robert W., additional, Brooker, Simon J., additional, Brooks, W. Abdullah, additional, Brouqui, Philippe, additional, Brown, Michael, additional, Brown, Michael R., additional, Broyles, Laura N., additional, Bruschi, Fabrizio, additional, Bundy, Donald A.P., additional, Burton, Matthew, additional, Cabrera-Sosa, Luis, additional, Callahan, Michael V., additional, Carapetis, Jonathan R., additional, Cardemil, Cristina V., additional, Carrol, Enitan D., additional, Caswell, Rachel, additional, Caumes, Eric, additional, Cavalheiro, Ana P., additional, Chan, Abner L., additional, Charunwatthana, Prakaykaew, additional, Checkley, Anna M., additional, Chen, Lin H., additional, Chher, Tepirou, additional, Chiong, Charlotte M., additional, Chisti, M. Jobayer, additional, Christiani, David C., additional, Clark, Taryn N., additional, Connor, Bradley A., additional, Conway, Devin J., additional, Cooper, Philip J., additional, Cope, Jennifer R., additional, Coughlin, R. Richard, additional, Coulibaly, Yaya I., additional, Coyle, Christina M., additional, Crozier, Ian, additional, Cunliffe, Nigel A., additional, Cupido, Blanche, additional, Curren, Emily J., additional, Danta, Mark, additional, Day, Nicholas P.J., additional, Debboun, Mustapha, additional, DeFraites, Robert F., additional, Dekumyoy, Paron, additional, del Castillo, Maria, additional, den Hoed, Caroline M., additional, de Silva, Nilanthi, additional, Deye, Gregory, additional, Dillingham, Rebecca A., additional, Drancourt, Michel, additional, Durward, Callum S., additional, Eddleston, Michael, additional, El-Kamary, Samer S., additional, Elshaboury, Ramy H., additional, Endtz, Hubert P., additional, Endy, Timothy P., additional, Fang, Shona C., additional, Fawzi, Wafaie, additional, Feasey, Nicholas A., additional, Field, Vanessa K., additional, Fischer, Marc, additional, Forsyth, Kevin, additional, Fournier, Pierre-Edouard, additional, Friedlander, Arthur M., additional, Furin, Jennifer J., additional, Gandhi, Ronak G., additional, Garcia, Hector H., additional, Garcia, Lynne S., additional, Geretti, Anna Maria, additional, Gikas, Achilleas, additional, Gilman, Robert H., additional, Giri, Sidhartha, additional, Gkika, Meropi, additional, Gordon, Melita A., additional, Gosselin, Richard A., additional, Gotuzzo, Eduardo, additional, Gould, Carolyn V., additional, Graeff-Teixeira, Carlos, additional, Graham, Stephen M., additional, Grant, Alison D., additional, Graybill, John R., additional, Graz, Bertrand, additional, Green, Stephen T., additional, Griffiths, Jeffrey K., additional, Griffiths, Michael J., additional, Gryseels, Bruno, additional, Gubler, Duane J., additional, Guhadasan, Rathi, additional, Hall, Aron J., additional, Hamer, Davidson H., additional, Hand, Robert M., additional, Harley, David, additional, Harris, Jason B., additional, Hassall, Oliver, additional, Hay, Roderick J., additional, Hickey, Patrick, additional, Hill, David R., additional, Hills, Susan L., additional, Hobdell, Martin H., additional, Hochberg, Natasha S., additional, Hopkins, Donald R., additional, Hossain, M. Iqbal, additional, Hotez, Peter J., additional, Howard, Cynthia R., additional, Hu, Victor, additional, Hung, Chien-Ching, additional, Islam, Munirul, additional, Iturriza-Gómara, Miren, additional, Joekes, Elizabeth, additional, Johnston, Victoria, additional, Jose, Jo-Ann, additional, Junghanss, Thomas, additional, Kamgno, Joseph, additional, Kampondeni, Sam, additional, Kang, Gagandeep, additional, Kazanjian, Powel, additional, Keshtkar-Jahromi, Maryam, additional, Keshtkar-Jahromi, Marzieh, additional, Keystone, Jay S., additional, Kim, Arthur Y., additional, Kim, Sung-Han, additional, King, Christopher L., additional, Kittitrakul, Chatporn, additional, Kleine, Christian, additional, Klion, Amy D., additional, Knight, Richard, additional, Koren, Michael, additional, Kottilil, Shyamasundaran, additional, Krause, Peter J., additional, Krishna, Sanjeev, additional, Kuhn, Jens H., additional, Kuipers, Ernst J., additional, LaBeaud, Angelle D., additional, Labra, Patrick John P., additional, Lalloo, David G., additional, Lambert, Saba, additional, Lanternier, Fanny, additional, LaRocque, Regina C., additional, Last, Anna, additional, Lawrenson, John, additional, Le, Thuy, additional, Lee, Keun Hwa, additional, Lewis, David A., additional, Libraty, Daniel H., additional, Lo, Nathan C., additional, Lockwood, Diana N.J., additional, Lockwood, Stephen J., additional, Lommerse, Kinke, additional, López-Vélez, Rogelio, additional, Lortholary, Olivier, additional, Mabey, David, additional, Magill, Alan J., additional, Maguiña, Ciro P., additional, Manji, Hadi, additional, Marks, Michael, additional, Maurin, Max, additional, Mayaud, Philippe, additional, Mayosi, Bongani M., additional, M'baya, Bridon, additional, McCarthy, Matthew W., additional, McCartney, Daniel, additional, McCormick, Joseph B., additional, McKew, Stephen, additional, McLellan, Susan L.F., additional, McMinn, Peter C., additional, Mertz, Gregory, additional, Milner, Danny A., additional, Molyneux, Elizabeth M., additional, Montgomery, Susan P., additional, Moonah, Shannon, additional, Moss, William J., additional, Murrell, K. Darwin, additional, Nanda, Neha, additional, Navarro, Eileen E., additional, Ndayizeye, Leonard, additional, Neafie, Ronald C., additional, Negroni, Ricardo, additional, Nelson, Ann M., additional, Newton, Paul N., additional, Nichol, Stuart T., additional, Norman, Francesca F., additional, Nunes, Marcio R.T., additional, Nutman, Thomas B., additional, Nyirenda, Tonney S., additional, Ochoa, Theresa J., additional, O'Farrell, Nigel, additional, Olayemi, Edeghonghon, additional, Oldfield, Edward C., additional, Omidian, Zahra, additional, Ordaya, Eloy E., additional, Paddock, Christopher D., additional, Paessler, Slobodan, additional, Papanikolaou, Ilias C., additional, Paris, Luc, additional, Parry, Christopher M., additional, Patel, Pragna, additional, Peacock, Sharon J., additional, Peeling, Rosanna W., additional, Persson, Hans, additional, Phillips, Jonathan J., additional, Phillips, Richard O., additional, Poovorawan, Kittiyod, additional, Powers, Ann M., additional, Qamar, Farah Naz, additional, Qureshi, Sonia, additional, Rabe, Ingrid B., additional, Rahman, Atif, additional, Rahmati, Elham, additional, Raizes, Elliot, additional, Ramalho-Ortigao, Marcelo, additional, Raoult, Didier, additional, Rein, Michael F., additional, Retik, Alan B., additional, Reynes, Jean-Marc, additional, Rhatigan, Joseph J., additional, Rickard, Jennifer, additional, Riddle, Mark S., additional, Rimoin, Anne W., additional, Riviello, Robert, additional, Robert, Leon L., additional, Rodrigues, Ema G., additional, Rodriguez, Rubens, additional, Ronald, Allan R., additional, Rosenthal, Benjamin M., additional, Rosmarin, David, additional, Ryan, Edward T., additional, Saavedra, Arturo, additional, Schiaffino, Francesca, additional, Schumacher, Sandra K., additional, Sejvar, James J., additional, Sethi, Aisha, additional, Seung, Kwonjune J., additional, Seydel, Karl B., additional, Shah, Melisa M., additional, Shakoor, Sadia, additional, Shankar, Anuraj H., additional, Sharp, Trueman W., additional, Shin, Sonya S., additional, Shirley, Debbie-Ann, additional, Silachamroon, Udomsak, additional, Smith, Catherine C., additional, Snelling, Thomas L., additional, Solomon, Tom, additional, Staat, Mary Allen, additional, Staples, J. Erin, additional, Steiger, Samantha N., additional, Stewart, Robert C., additional, Stich, August, additional, Strickman, Daniel, additional, Suh, Kathryn N., additional, Suhrbier, Andreas, additional, Sutcliffe, Catherine G., additional, Tappe, Dennis, additional, Taylor, Terrie E., additional, Thanh, Nguyen Tat, additional, Thanh, Nguyen Thi, additional, Thwaites, C. Louise, additional, Thwaites, Guy E., additional, Tiwari, Tejpratap S.P., additional, Tsenempi, Xenia A., additional, Turner, Angus W., additional, van den Broek, Nynke R., additional, van Doorn, H. Rogier, additional, Van Sickels, Nicholas J., additional, Vannier, Edouard, additional, Varda, Briony K., additional, Vasconcelos, Pedro F.C., additional, Vega-López, Francisco, additional, Vietri, Nicholas J., additional, Vinetz, Joseph M., additional, Visvesvara, Govinda S., additional, Vyas, Keyur S., additional, Walsh, Thomas J., additional, Wansbrough-Jones, Mark H., additional, Warraich, Haider J., additional, Warrell, David A., additional, Warrell, Mary J., additional, Watt, George, additional, Wattanagoon, Yupaporn, additional, Watthanakulpanich, Dorn, additional, Weaver, Scott C., additional, Weil, Ana A., additional, Weiss, Louis M., additional, White, Nicholas J., additional, Whitty, Christopher J.M., additional, Wilson, Mary E., additional, Xavier, Ramnik J., additional, Xiao, Lihua, additional, Yoon, In-Kyu, additional, Yu, Hongjie, additional, and Zaidi, Anita K.M., additional

Published
2020
Full Text
View/download PDF

8. Tuberculosis

Author

Cavalhiero, Ana P., primary, Shin, Sonya S., additional, Seung, Kwonjune J., additional, and Furin, Jennifer J., additional

Published
2020
Full Text
View/download PDF

9. Effectiveness of Bedaquiline Use Beyond Six Months in Patients with Multidrug-Resistant Tuberculosis

Author

Trevisi, Letizia, primary, Hernán, Miguel A., additional, Mitnick, Carole D, additional, Khan, Uzma, additional, Seung, Kwonjune J, additional, Rich, Michael L., additional, Bastard, Mathieu, additional, Huerga, Helena, additional, Melikyan, Nara, additional, Atwood, Sidney, additional, Avaliani, Zaza, additional, Llanos, Felix, additional, Manzur-ul-Alam, Mohammed, additional, Zarli, Khin, additional, Binedgie, Amsalu Bekele, additional, Adnan, Sana, additional, Melikyan, Arusyak, additional, Gelin, Alain, additional, Isani, Afshan K, additional, Vetushko, Dmitry, additional, Daugarina, Zhenisgul, additional, Nkundanyirazo, Patrick, additional, Putri, Fauziah Asnely, additional, Vilbrun, Charles, additional, Khan, Munira, additional, Hewison, Catherine, additional, Khan, Palwasha Y, additional, and Franke, Molly F, additional

Published
2023
Full Text
View/download PDF

11. Treatment Outcomes of Patients With Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis According to Drug Susceptibility Testing to First- and Second-line Drugs: An Individual Patient Data Meta-analysis

Author

Collaborative Group for Meta-analysis of Individual Patient Data in MDR-TB, Bastos, Mayara L., Hussain, Hamidah, Weyer, Karin, Garcia-Garcia, Lourdes, Leimane, Vaira, Leung, Chi Chiu, Narita, Masahiro, Penã, Jose M., Ponce-de-Leon, Alfredo, Seung, Kwonjune J., Shean, Karen, Sifuentes-Osornio, José, Van der Walt, Martie, Van der Werf, Tjip S., Yew, Wing Wai, and Menzies, Dick

Published
2014
Full Text
View/download PDF

12. Incidence of high grade qtcf prolongation and its management among patients undergoing treatment for drug resistant tuberculosis (DR-TB): case series

Author

Asfaw, Meseret T., Holtzman, David L., Kwan, Gene F., Oyewusi, Lawrence T., Mitnick, Carole D., and Seung, Kwonjune J

Subjects
QT-interval Prolongation, Bedaquiline, Delamanid, Drug Resistant Tuberculosis
Abstract

Background: The World Health Organization (WHO) has approved the use of two new drugs, namely Bedaquiline (Bdq) and Delamanid (Dlm), for treatment of Drug Resistant Tuberculosis (DR-TB). One of the concerns raised with the use of these drugs was QT-interval prolongation. This condition could be serious and life threatening. Hence, knowing the magnitude and its management is very important. This case series identifies the incidence and discusses the management of clinically significant QT-interval prolongation amongst a cohort of patients who have been on these medicines.Materials and Methods: Patients with reports of high grade QT-Interval prolongation (i.e. Grade-3 and Grade-4) were identified from the cohort of 265 patients enrolled on bedaquiline and/or delamanid and discussion is made on the pattern, severity and management of each cases identified.Results: Only 4 (1.5%) out of all 265 patients enrolled on Bedaquiline and/or Delamanid have developed high grade QT-Interval prolongation. And all are managed without permanent discontinuation of both drugs.Conclusion: The Incidence of clinically significant QTcF-interval prolongation among DR-TB patients taking bedaquiline and /or delamanid in Lesotho is low. And almost all cases can be managed with more frequent Electrocardiogram (ECG) monitoring and management of other possible causes of QT-interval prolongation without the need to stop one or both drugs permanently.

Published
2022

13. Corrigendum to ‘Culture conversion at six months in patients receiving bedaquiline- and delamanid-containing regimens for the treatment of multidrug-resistant tuberculosis’ International Journal of Infectious Diseases Volume 113S1 (2021) S91-S95

Author

Maretbayeva, Shynar M., primary, Rakisheva, Anar S., additional, Adenov, Malik M., additional, Yeraliyeva, Lyazzat T., additional, Algozhin, Yerkebulan Zh., additional, Stambekova, Assel T., additional, Berikova, Elmira A., additional, Yedilbayev, Askar, additional, Rich, Michael L., additional, Seung, Kwonjune J., additional, and Issayeva, Assiya M., additional

Published
2022
Full Text
View/download PDF

16. Safety and effectiveness outcomes from a 14-country cohort of patients with multi-drug resistant tuberculosis treated concomitantly with bedaquiline, delamanid and other second-line drugs

Author

Huerga, Helena, Khan, Uzma, Bastard, Mathieu, Mitnick, Carole D, Lachenal, Nathalie, Khan, Palwasha Y, Seung, Kwonjune J, Melikyan, Nara, Ahmed, Saman, Rich, Michael L, Varaine, Francis, Osso, Elna, Rashitov, Makhmujan, Salahuddin, Naseem, Salia, Gocha, Sánchez, Epifanio, Serobyan, Armine, Siddiqui, Muhammad Rafi, Tefera, Dri Grium, Vetushko, Dmitry, Yeghiazaryan, Lusine, Holtzman, David, Islam, Shirajul, Kumsa, Andargachew, Leblanc, Gamarly Jacques, Leonovich, Olga, Mamsa, Shahid, Manzur-Ul-Alam, Mohammad, Myint, Zaw, Padayachee, Shrivani, Franke, Molly F, Hewison, Catherine, and endTB study observational study team

Abstract

BACKGROUND: Concomitant use of bedaquiline (Bdq) and delamanid (Dlm) for multi-drug/rifampicin resistant tuberculosis (MDR/RR-TB) has raised concerns about a potentially poor risk-benefit ratio. Yet, this combination is an important alternative for patients infected with strains of TB with complex drug resistance profiles or who cannot tolerate other therapies. We assessed safety and treatment outcomes of MDR/RR-TB patients receiving concomitant Bdq and Dlm, along with other second-line anti-TB drugs. METHODS: We conducted a multi-centric, prospective observational cohort study across 14 countries among patients receiving concomitant Bdq-Dlm treatment. Patients were recruited between April 2015 and September 2018 and were followed until the end of treatment. All serious adverse events and adverse events of special interest (AESI), leading to a treatment change, or judged significant by a clinician, were systematically monitored and documented. RESULTS: Overall, 472 patients received Bdq and Dlm concomitantly. A large majority also received linezolid (89.6%) and clofazimine (84.5%). Nearly all (90.3%) had extensive disease; most (74.2%) had resistance to fluoroquinolones. The most common AESI were peripheral neuropathy (134, 28.4%) and electrolyte depletion (94, 19.9%). Acute kidney injury and myelosuppression were seen in 40 (8.5%) and 24 (5.1%) of patients, respectively. QT prolongation occurred in 7 (1.5%). Overall, 78.0% (358/458) had successful treatment outcomes, 8.9% died and 7.2% experienced treatment failure. CONCLUSIONS: Concomitant use of Bdq and Dlm, along with linezolid and clofazimine, is safe and effective for MDR/RR-TB patients with extensive disease. Using these drugs concomitantly is a good therapeutic option for patients with resistance to many anti-TB drugs.

Published
2022

18. Safety of Treatment Regimens Containing Bedaquiline and Delamanid in the endTB Cohort

Author

Hewison, Catherine, primary, Khan, Uzma, additional, Bastard, Mathieu, additional, Lachenal, Nathalie, additional, Coutisson, Sylvine, additional, Osso, Elna, additional, Ahmed, Saman, additional, Khan, Palwasha, additional, Franke, Molly F, additional, Rich, Michael L, additional, Varaine, Francis, additional, Melikyan, Nara, additional, Seung, Kwonjune J, additional, Adenov, Malik, additional, Adnan, Sana, additional, Danielyan, Narine, additional, Islam, Shirajul, additional, Janmohamed, Aleeza, additional, Karakozian, Hayk, additional, Kamene Kimenye, Maureen, additional, Kirakosyan, Ohanna, additional, Kholikulov, Begimkul, additional, Krisnanda, Aga, additional, Kumsa, Andargachew, additional, Leblanc, Garmaly, additional, Lecca, Leonid, additional, Nkuebe, Mpiti, additional, Mamsa, Shahid, additional, Padayachee, Shrivani, additional, Thit, Phone, additional, Mitnick, Carole D, additional, and Huerga, Helena, additional

Published
2022
Full Text
View/download PDF

21. All-oral longer regimens are effective for the management of multidrug-resistant tuberculosis in high-burden settings

Author

Khan, Palwasha Y., primary, Franke, Molly F., additional, Hewison, Catherine, additional, Seung, Kwonjune J., additional, Huerga, Helena, additional, Atwood, Sidney, additional, Ahmed, Saman, additional, Khan, Munira, additional, Sultana, Tanha, additional, Manzur-ul-Alam, Mohammad, additional, Vo, Luan N.Q., additional, Lecca, Leonid, additional, Yae, Kalkidan, additional, Kozhabekov, Serik, additional, Tamirat, Meseret, additional, Gelin, Alain, additional, Vilbrun, Stalz C., additional, Kikvidze, Marina, additional, Faqirzai, Jamil, additional, Kadyrov, Abdullaat, additional, Skrahina, Alena, additional, Mesic, Anita, additional, Avagyan, Nana, additional, Bastard, Mathieu, additional, Rich, Michael L., additional, Khan, Uzma, additional, and Mitnick, Carole D., additional

Published
2021
Full Text
View/download PDF

23. Culture Conversion in Patients Treated with Bedaquiline and/or Delamanid. A Prospective Multicountry Study

Author

Franke, Molly F., primary, Khan, Palwasha, additional, Hewison, Cathy, additional, Khan, Uzma, additional, Huerga, Helena, additional, Seung, Kwonjune J., additional, Rich, Michael L., additional, Zarli, Khin, additional, Samieva, Nazgul, additional, Oyewusi, Lawrence, additional, Nair, Parvati, additional, Mudassar, Mishaz, additional, Melikyan, Nara, additional, Lenggogeni, Putri, additional, Lecca, Leonid, additional, Kumsa, Andargachew, additional, Khan, Munira, additional, Islam, Shirajul, additional, Hussein, Kerow, additional, Docteur, Wisny, additional, Chumburidze, Nino, additional, Berikova, Elmira, additional, Atshemyan, Hakob, additional, Atwood, Sidney, additional, Alam, Manzurul, additional, Ahmed, Saman, additional, Bastard, Mathieu, additional, and Mitnick, Carole D., additional

Published
2021
Full Text
View/download PDF

24. Comprehensive treatment of extensively drug-resistant tuberculosis

Author

Mitnick, Carole D., Shin, Sonya S., Seung, Kwonjune J., Rich, Michael L., Atwood, Sidney S., Furin, Jennifer J., Fitzmaurice, Garrett M., Viru, Felix A. Alcantara, Appleton, Sasha C., Bayona, Jaime N., Bonilla, Cesar A., Chalco, Katiuska, Choi, Sharon, Franke, Molly F., Fraser, Hamish S.F., Guerra, Dalia, Hurtado, Rocio M., Jazayeri, Darius, Joseph, Keith, Llaro, Karim, Mestanza, Lorena, Mukherjee, Joia S., Munoz, Maribel, Palacios, Eda, Sanchez, Epifanio, Sloutsky, Alexander, and Becerra, Mercedes C.

Subjects
Tuberculosis -- Diagnosis, Tuberculosis -- Risk factors, Tuberculosis -- Care and treatment, Tuberculosis -- Patient outcomes, Ambulatory medical care -- Services
Abstract

A study was conducted to evaluate the comprehensive treatment outcomes for patients with extensively drug-resistant tuberculosis. Results indicated that extensively drug-resistant tuberculosis in HIV-negative patients can be cured through outpatient treatment.

Published
2008

26. List of Contributors

Author

Acuin, Jose M, primary, Adam, Rodney D, additional, Agbenyega, Tsiri, additional, Ahmed, AM Shamsir, additional, Ahmed, Tahmeed, additional, Ali, S Asad, additional, Anstead, Gregory M, additional, Armah, George E, additional, Aston, Stephen J, additional, Ballard, Ronald C, additional, Barnett, Elizabeth D, additional, Bates, Imelda, additional, Beadling, Charles W, additional, Beeching, Nicholas J, additional, Bennish, Michael L, additional, Bern, Caryn, additional, Bia, Frank J, additional, Bird, Brian H, additional, Bloom, Allyson K, additional, Bodeker, Gerard, additional, Bradsher, Robert W, additional, Broek, Nynke van den, additional, Brooker, Simon, additional, Brooks, John T, additional, Brooks, W Abdullah, additional, Brouqui, Philippe, additional, Brown, Michael, additional, Bruschi, Fabrizio, additional, Bundy, Donald AP, additional, Bunnag, Danai, additional, Caballero, Benjamin, additional, Callahan, Michael V, additional, Camerlin, Aulasa J, additional, Campbell, Grant L, additional, Carapetis, Jonathan R, additional, Carrol, Enitan D, additional, Caumes, Eric, additional, Charrel, Remi N, additional, Checkley, Anna M, additional, Chhabra, Mala, additional, Chher, Tepirou, additional, Chiong, Charlotte M, additional, Chisti, M Jobayer, additional, Christiani, David C, additional, Connor, Bradley A, additional, Cooper, Edward S, additional, Cooper, Philip J, additional, Coughlin, R Richard, additional, Cross, John H, additional, Cunliffe, Nigel N, additional, Danta, Mark, additional, Day, Nicholas PJ, additional, Dekumyoy, Paron, additional, deSilva, Nilanthi, additional, Deye, Gregory, additional, Dillingham, Rebecca, additional, Doorn, H Rogier van, additional, Doudier, Barbara, additional, Drancourt, Michel, additional, Dromer, Françoise, additional, Eddleston, Michael, additional, El-Kamary, Samer S, additional, Farrar, Jeremy, additional, Fawzi, Wafaie, additional, Feasey, Nicholas A, additional, Field, Vanessa, additional, Fischer, Marc, additional, Fisher-Hoch, Susan, additional, Forsyth, Kevin, additional, Fox, LeAnne M, additional, Friedlander, Arthur M, additional, Galdos-Cardenas, Gerson, additional, Garcia, Hector H, additional, Garcia, Lynne S, additional, Geretti, Anna-Maria, additional, Gikas, Achilleas, additional, Gilman, Robert H, additional, Gonzalez, Victor Javier Sanchez, additional, Gordon, Melita A, additional, Gosselin, Richard A, additional, Graham, Stephen M, additional, Grant, Alison D, additional, Gray, James J, additional, Graybill, John R, additional, Graz, Bertrand, additional, Green, Stephen, additional, Griffiths, Jeffrey K, additional, Gryseels, Bruno, additional, Gubler, Duane J, additional, Guhadasan, Rathi, additional, Hall, Aron J, additional, Hamer, Davidson, additional, Harley, David, additional, Harris, Jason B, additional, Hartman, Amy L, additional, Hassall, Oliver, additional, Hay, Roderick J, additional, Heyns, Chris F, additional, Hill, David R, additional, Hobdell, Martin H, additional, Hoed, Caroline M den, additional, Holtz, Meredith L, additional, Hossain, M Iqbal, additional, Hotez, Peter J, additional, Houpt, Eric R, additional, Howard, Cynthia R, additional, Hung, Chien-Ching, additional, Islam, Munirul, additional, Joekes, Elizabeth, additional, Johnston, Victoria, additional, Kampondeni, Sam, additional, Kang, Gagandeep, additional, Kazanjian, Powel, additional, Keystone, Jay S, additional, Khan, Wasif Ali, additional, Kim, Arthur Y, additional, King, Christopher L, additional, Klion, Amy D, additional, Knight, Richard, additional, Krause, Peter James, additional, Krishna, Sanjeev, additional, Kuipers, Ernst J, additional, LaBeaud, Angelle D, additional, Lalloo, David G, additional, Lamballerie, Xavier De, additional, Lambert, Saba, additional, LaRocque, Regina C, additional, Lawrenson, John, additional, Levine, Myron M, additional, Libraty, Daniel H, additional, Lockwood, Diana NJ, additional, Lommerse, Kinke M, additional, Lortholary, Olivier, additional, López-Vélez, Rogelio, additional, Lopman, Benjamin A, additional, Mabey, David, additional, Magill, Alan J., additional, Maguiña, Ciro, additional, Mahmood, Syed Faisal, additional, Maitland, Kathryn, additional, Manji, Hadi, additional, Marston, Barbara J, additional, Mathew, Anu, additional, Mathews, Christine E, additional, Maurin, Max, additional, Maurtua-Neumann, Paola J, additional, Mayaud, Philippe, additional, Mayosi, Bongani M, additional, McCormick, Joseph B, additional, McKew, Stephen, additional, McLellan, Susan LF, additional, McMinn, Peter C, additional, Mega, Joseph D, additional, Meier, Donald E, additional, Million, Matthieu, additional, Mittal, Veena, additional, Molyneux, Elizabeth M, additional, Montgomery, Susan P, additional, Morera, Pedro, additional, Moro, Pedro L, additional, Moss, William J, additional, Murrell, K Darwin, additional, Nakagomi, Osamu, additional, Nakagomi, Toyoko, additional, Nanda, Neha, additional, Nataro, James P, additional, Navaro, Eileen E, additional, Neafie, Ronald C, additional, Negroni, Ricardo, additional, Nelson, Ann M, additional, Newton, Paul N, additional, Newton, Robert, additional, Nichol, Stuart T, additional, Norman, Francesca F, additional, Nunes, Marcio RT, additional, Nutman, Thomas B, additional, Oberhelman, Richard A, additional, Oldfield, Edward C, additional, Ordaya, Eloy E, additional, Paddock, Christopher D, additional, Paessler, Slobodan, additional, Papanikolaou, Ilias C, additional, Pappas, Georgios, additional, Paris, Luc, additional, Parola, Philippe, additional, Parry, Christopher M, additional, Patel, Manish M, additional, Peacock, Sharon J, additional, Peeling, Rosanna, additional, Persson, Hans, additional, Peters, Philip J, additional, Phillips, Jonathan J, additional, Phillips, Richard O, additional, Qamar, Farah Naz, additional, Rahman, Atif, additional, Rajab, Jamilla, additional, Raoult, Didier, additional, Rein, Michael F, additional, Renvoisé, Aurélié, additional, Reynes, Jean-Marc, additional, Richards, Frank O, additional, Richens, John, additional, Rimoin, Anne W, additional, Riviello, Robert, additional, Rodrigues, Ema G, additional, Ronald, Allan R, additional, Rosenthal, Benjamin M, additional, Rosmarin, David, additional, Ruiz-Tiben, Ernesto, additional, Ryan, Edward T, additional, Saha, Debasish, additional, Saavedra, Arturo, additional, Schantz, Peter M, additional, Schountz, Tony, additional, Schumacher, Sandra K, additional, Sejvar, James J, additional, Sethi, Aisha, additional, Seung, Kwonjune J, additional, Sharma, Om Prakash, additional, Sharp, Trueman W, additional, Shankar, Anuraj H, additional, Shin, Sonya S, additional, Shlim, David R, additional, Sickels, Nicholas J van, additional, Sitas, Freddy, additional, Snelling, Thomas L, additional, Socolovschi, Cristina, additional, Solomon, Tom, additional, Staples, J Erin, additional, Stewart, Robert C, additional, Stich, August, additional, Strickland, G Thomas, additional, Suh, Kathryn N, additional, Suhrbier, Andreas, additional, Supparatpinyo, Khuanchai, additional, Sutcliffe, Catherine G, additional, Swierczewski, Brett E, additional, Tarpley, John L, additional, Taylor, Hugh R, additional, Taylor, Terrie, additional, Thomas, Harry J, additional, Thwaites, C Louise, additional, Thwaites, Guy E, additional, Tiwari, Tejpratap SP, additional, Tu, Phan Van, additional, Turner, Angus W, additional, Vannier, Edouard, additional, Vasconcelos, Pedro FC, additional, Vega-López, Fransisco, additional, Velarde, Jorge J, additional, Vietri, Nicholas J, additional, Visvesvara, Govinda S, additional, Vyas, Keyur S, additional, Wakeham, Katie, additional, Walsh, Thomas J, additional, Wansbrough-Jones, Mark H, additional, Warrell, David A, additional, Warrell, Mary J, additional, Warraich, Haider J, additional, Watt, George, additional, Wattanagoon, Yupaporn, additional, Watthanakulpanich, Dorn, additional, Weaver, Scott C, additional, Webman, Rachel B, additional, Weidle, Paul J, additional, Weiss, Louis M, additional, White, Nicholas J, additional, Whitty, Christopher JM, additional, Woodhall, Dana M, additional, Wright, Stephen G, additional, Xavier, Ramnik J, additional, Xiao, Lihua, additional, Yu, Hongjie, additional, and Zaidi, Anita KM, additional

Published
2013
Full Text
View/download PDF

28. Treatment of multidrug-resistant tuberculosis during pregnancy: a report of 7 cases. (Major Article)

Author

Shin, Sonya, Guerra, Dalia, Rich, Michael, Seung, Kwonjune J., Mukherjee, Joia, Joseph, Keith, Hurtado, Rocio, Alcantara, Felix, Bayona, Jaime, Bonilla, Cesar, Farmer, Paul, and Furin, Jennifer

Subjects
Drug resistance in microorganisms -- Research, Pregnant women -- Care and treatment, Pregnant women -- Diseases, Communicable diseases -- Research, Tuberculosis -- Statistics, Tuberculosis -- Drug therapy, Health, Health care industry
Published
2003

30. Culture Conversion at 6 Months in Patients Receiving Delamanid-containing Regimens for the Treatment of Multidrug-resistant Tuberculosis

Author

Seung, Kwonjune J, primary, Khan, Palwasha, additional, Franke, Molly F, additional, Ahmed, Saman, additional, Aiylchiev, Stalbek, additional, Alam, Manzur, additional, Putri, Fauziah Asnely, additional, Bastard, Mathieu, additional, Docteur, Wisny, additional, Gottlieb, Gary, additional, Hewison, Catherine, additional, Islam, Shirajul, additional, Khachatryan, Naira, additional, Kotrikadze, Tinatin, additional, Khan, Uzma, additional, Kumsa, Andargachew, additional, Lecca, Leonid, additional, Tassew, Yoseph Melaku, additional, Melikyan, Nara, additional, Naing, Ye Yint, additional, Oyewusi, Lawrence, additional, Rich, Michael, additional, Wanjala, Stephen, additional, Yedilbayev, Askar, additional, Huerga, Helena, additional, and Mitnick, Carole D, additional

Published
2019
Full Text
View/download PDF

31. Multidrug-Resistant Tuberculosis Treatment in North Korea: Is Scale-Up Possible?

Author

Seung, Kwonjune J., Franke, Molly, and Linton, Stephen W.

Subjects
LEDs -- Usage, Fluorescence microscopy -- Usage, Microbial drug resistance -- Drug therapy -- Research, Public health -- Analysis -- Management, Wellness programs -- Management, Tuberculosis -- Drug therapy -- Care and treatment, Company business management, Biological sciences, World Health Organization
Abstract

Author(s): Kwonjune J. Seung 1,2,3,4,*, Molly Franke 2,4, Stephen W. Linton 1 Summary Points Multidrug-resistant tuberculosis (MDR TB) is one of the most serious public health problems facing North Korea, [...]

Published
2016
Full Text
View/download PDF

34. BMP5 and the molecular, skeletal, and soft-tissue alterations in short ear mice

Author

King, Jennifer A., Marker, Paul C., Seung, Kwonjune J., and Kingsley, David M.

Subjects
Mice -- Genetic aspects, Mutation (Biology) -- Analysis, Tissues -- Growth, Biological sciences
Abstract

Analysis of mutations in the mouse short ear (se) locus reveals a nonsense mutation in the secreted signaling molecule, bone morphogenetic protein 5 (BMP5), indicating that BMP5 is the normal se gene product. BMP5 gene transcript expression is seen in liver, ureter, lungs, bladder, soft tissues and intestines. Biochemical and genetic data indicate that BMP5 is the main mediator of soft tissue development and skeletal patterning.

Published
1994

35. Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis

Author

Collaborative Group for the Meta-Analysis of Individual Patient Data in MDR-TB treatment–2017, Ahmad, Nafees, Ahuja, Shama D, Akkerman, Onno W, Alffenaar, Jan-Willem C, Anderson, Laura F, Baghaei, Parvaneh, Bang, Didi, Barry, Pennan M, Bastos, Mayara L, Behera, Digamber, Benedetti, Andrea, Bisson, Gregory P, Boeree, Martin J, Bonnet, Maryline, Brode, Sarah K, Brust, James CM, Cai, Ying, Caumes, Eric, Cegielski, J Peter, Centis, Rosella, Chan, Pei-Chun, Chan, Edward D, Chang, Kwok-Chiu, Charles, Macarthur, Cirule, Andra, Dalcolmo, Margareth Pretti, D'Ambrosio, Lia, de Vries, Gerard, Dheda, Keertan, Esmail, Aliasgar, Flood, Jennifer, Fox, Gregory J, Fréchet-Jachym, Mathilde, Fregona, Geisa, Gayoso, Regina, Gegia, Medea, Gler, Maria Tarcela, Gu, Sue, Guglielmetti, Lorenzo, Holtz, Timothy H, Hughes, Jennifer, Isaakidis, Petros, Jarlsberg, Leah, Kempker, Russell R, Keshavjee, Salmaan, Khan, Faiz Ahmad, Kipiani, Maia, Koenig, Serena P, Koh, Won-Jung, Kritski, Afranio, Kuksa, Liga, Kvasnovsky, Charlotte L, Kwak, Nakwon, Lan, Zhiyi, Lange, Christoph, Laniado-Laborín, Rafael, Lee, Myungsun, Leimane, Vaira, Leung, Chi-Chiu, Leung, Eric Chung-Ching, Li, Pei Zhi, Lowenthal, Phil, Maciel, Ethel L, Marks, Suzanne M, Mase, Sundari, Mbuagbaw, Lawrence, Migliori, Giovanni B, Milanov, Vladimir, Miller, Ann C, Mitnick, Carole D, Modongo, Chawangwa, Mohr, Erika, Monedero, Ignacio, Nahid, Payam, Ndjeka, Norbert, O'Donnell, Max R, Padayatchi, Nesri, Palmero, Domingo, Pape, Jean William, Podewils, Laura J, Reynolds, Ian, Riekstina, Vija, Robert, Jérôme, Rodriguez, Maria, Seaworth, Barbara, Seung, Kwonjune J, Schnippel, Kathryn, Shim, Tae Sun, Singla, Rupak, Smith, Sarah E, Sotgiu, Giovanni, Sukhbaatar, Ganzaya, Tabarsi, Payam, Tiberi, Simon, Trajman, Anete, Trieu, Lisa, Udwadia, Zarir F, van der Werf, Tjip S, and Veziris, Nicolas

Subjects
Collaborative Group for the Meta-Analysis of Individual Patient Data in MDR-TB treatment–2017, Moxifloxacin, Clinical Trials and Supportive Activities, Antitubercular Agents, Levofloxacin, Clofazimine, Medical and Health Sciences, Rare Diseases, Drug Therapy, Recurrence, Kanamycin, Clinical Research, General & Internal Medicine, Humans, Tuberculosis, Treatment Failure, Capreomycin, Diarylquinolines, Amikacin, Lung, Prevention, Linezolid, Evaluation of treatments and therapeutic interventions, Pulmonary, Multidrug-Resistant, Orphan Drug, Good Health and Well Being, Carbapenems, 6.1 Pharmaceuticals, Combination, Antimicrobial Resistance, Infection, Fluoroquinolones
Abstract

BackgroundTreatment outcomes for multidrug-resistant tuberculosis remain poor. We aimed to estimate the association of treatment success and death with the use of individual drugs, and the optimal number and duration of treatment with those drugs in patients with multidrug-resistant tuberculosis.MethodsIn this individual patient data meta-analysis, we searched MEDLINE, Embase, and the Cochrane Library to identify potentially eligible observational and experimental studies published between Jan 1, 2009, and April 30, 2016. We also searched reference lists from all systematic reviews of treatment of multidrug-resistant tuberculosis published since 2009. To be eligible, studies had to report original results, with end of treatment outcomes (treatment completion [success], failure, or relapse) in cohorts of at least 25 adults (aged >18 years). We used anonymised individual patient data from eligible studies, provided by study investigators, regarding clinical characteristics, treatment, and outcomes. Using propensity score-matched generalised mixed effects logistic, or linear regression, we calculated adjusted odds ratios and adjusted risk differences for success or death during treatment, for specific drugs currently used to treat multidrug-resistant tuberculosis, as well as the number of drugs used and treatment duration.FindingsOf 12 030 patients from 25 countries in 50 studies, 7346 (61%) had treatment success, 1017 (8%) had failure or relapse, and 1729 (14%) died. Compared with failure or relapse, treatment success was positively associated with the use of linezolid (adjusted risk difference 0·15, 95% CI 0·11 to 0·18), levofloxacin (0·15, 0·13 to 0·18), carbapenems (0·14, 0·06 to 0·21), moxifloxacin (0·11, 0·08 to 0·14), bedaquiline (0·10, 0·05 to 0·14), and clofazimine (0·06, 0·01 to 0·10). There was a significant association between reduced mortality and use of linezolid (-0·20, -0·23 to -0·16), levofloxacin (-0·06, -0·09 to -0·04), moxifloxacin (-0·07, -0·10 to -0·04), or bedaquiline (-0·14, -0·19 to -0·10). Compared with regimens without any injectable drug, amikacin provided modest benefits, but kanamycin and capreomycin were associated with worse outcomes. The remaining drugs were associated with slight or no improvements in outcomes. Treatment outcomes were significantly worse for most drugs if they were used despite in-vitro resistance. The optimal number of effective drugs seemed to be five in the initial phase, and four in the continuation phase. In these adjusted analyses, heterogeneity, based on a simulated I2 method, was high for approximately half the estimates for specific drugs, although relatively low for number of drugs and durations analyses.InterpretationAlthough inferences are limited by the observational nature of these data, treatment outcomes were significantly better with use of linezolid, later generation fluoroquinolones, bedaquiline, clofazimine, and carbapenems for treatment of multidrug-resistant tuberculosis. These findings emphasise the need for trials to ascertain the optimal combination and duration of these drugs for treatment of this condition.FundingAmerican Thoracic Society, Canadian Institutes of Health Research, US Centers for Disease Control and Prevention, European Respiratory Society, Infectious Diseases Society of America.

Published
2018

37. Agreement between physicians and non-physician clinicians in starting antiretroviral therapy in rural Uganda

Author

Vasan Ashwin, Kenya-Mugisha Nathan, Seung Kwonjune J, Achieng Marion, Banura Patrick, Lule Frank, Beems Megan, Todd Jim, and Madraa Elizabeth

Subjects
Medicine (General), R5-920, Public aspects of medicine, RA1-1270
Abstract

Abstract Background The scarcity of physicians in sub-Saharan Africa – particularly in rural clinics staffed only by non-physician health workers – is constraining access to HIV treatment, as only they are legally allowed to start antiretroviral therapy in the HIV-positive patient. Here we present a pilot study from Uganda assessing agreement between non-physician clinicians (nurses and clinical officers) and physicians in their decisions as to whether to start therapy. Methods We conducted the study at 12 government antiretroviral therapy sites in three regions of Uganda, all of which had staff trained in delivery of antiretroviral therapy using the WHO Integrated Management of Adult and Adolescent Illness guidelines for chronic HIV care. We collected seven key variables to measure patient assessment and the decision as to whether to start antiretroviral therapy, the primary variable of interest being the Final Antiretroviral Therapy Recommendation. Patients saw either a clinical officer or nurse first, and then were screened identically by a blinded physician during the same clinic visit. We measured inter-rater agreement between the decisions of the non-physician health workers and physicians in the antiretroviral therapy assessment variables using simple and weighted Kappa analysis. Results Two hundred fifty-four patients were seen by a nurse and physician, while 267 were seen by a clinical officer and physician. The majority (> 50%) in each arm of the study were in World Health Organization Clinical Stages I and II and therefore not currently eligible for antiretroviral therapy according to national antiretroviral therapy guidelines. Nurses and clinical officers both showed moderate to almost perfect agreement with physicians in their Final Antiretroviral Therapy Recommendation (unweighted κ = 0.59 and κ = 0.91, respectively). Agreement was also substantial for nurses versus physicians for assigning World Health Organization Clinical Stage (weighted κ = 0.65), but moderate for clinical officers versus physicians (κ = 0.44). Conclusion Both nurses and clinical officers demonstrated strong agreement with physicians in deciding whether to initiate antiretroviral therapy in the HIV patient. This could lead to immediate benefits with respect to antiretroviral therapy scale-up and decentralization to rural areas in Uganda, as non-physician clinicians – particularly clinical officers – demonstrated the capacity to make correct clinical decisions to start antiretroviral therapy. These preliminary data warrant more detailed and multicountry investigation into decision-making of non-physician clinicians in the management of HIV disease with antiretroviral therapy, and should lead policy-makers to more carefully explore task-shifting as a shorter-term response to addressing the human resource crisis in HIV care and treatment.

Published
2009
Full Text
View/download PDF

38. Treatment Outcomes of Patients With Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis According to Drug Susceptibility Testing to First- and Second-line Drugs

Author

Bastos, Mayara L., Hussain, Hamidah, Weyer, Karin, Garcia-Garcia, Lourdes, Leimane, Vaira, Leung, Chi Chiu, Narita, Masahiro, Penã, Jose M., Ponce-de-Leon, Alfredo, Seung, Kwonjune J., Shean, Karen, Sifuentes-Osornio, José, Van der Walt, Martie, Van der Werf, Tjip S., Yew, Wing Wai, Menzies, Dick, Ahuja, S., Ashkin, D., Avendaño, M., Banerjee, R., Bauer, M., Becerra, M., Benedetti, A., Burgos, M., Centis, R., Chan, E.D., Chiang, C.Y., Cobelens, F., Cox, H., D'Ambrosio, L., de Lange, W.C.M., DeRiemer, K., Enarson, D., Falzon, D., Flanagan, K., Flood, J., Gandhi, N., Garcia-Garcia, L., Granich, R.M., Hollm-Delgado, M.G., Holtz, T.H., Hopewell, P., Iseman, M., Jarlsberg, L.G., Keshavjee, S., Kim, H.R., Koh, W.J., Lancaster, J., Lange, C., Leimane, V., Leung, C.C., Li, J., Menzies, D., Migliori, G.B., Mitnick, C.M., Narita, M., Nathanson, E., Odendaal, R., O'Riordan, P., Pai, M., Palmero, D., Park, S.K., Pasvol, G., Pena, J., Pérez-Guzmán, C., Ponce-de-Leon, A., Quelapio, M.I.D., Quy, H.T., Riekstina, V., Robert, J., Royce, S., Salim, M., Schaaf, H.S., Seung, K.J., Shah, L., Shean, K., Shim, T.S., Shin, S.S., Shiraishi, Y., Sifuentes-Osornio, J., Sotgiu, G., Strand, M.J., Sung, S.W., Tabarsi, P., Tupasi, T.E., Vargas, M.H., van Altena, R., van der Walt, M., van der Werf, T.S., Viiklepp, P., Westenhouse, J., Yew, W.W., Yim, J.J., and Microbes in Health and Disease (MHD)

Subjects
Microbiology (medical), Drug, Adult, Male, medicine.medical_specialty, Tuberculosis, media_common.quotation_subject, Extensively Drug-Resistant Tuberculosis, PULMONARY TUBERCULOSIS, CITY, CALIFORNIA, Antitubercular Agents, drug susceptibility test, Microbial Sensitivity Tests, treatment outcomes, Pharmacology, THERAPY, Young Adult, Pharmacotherapy, Risk Factors, Internal medicine, Tuberculosis, Multidrug-Resistant, medicine, Odds Ratio, STANDARDIZED REGIMENS, MANAGEMENT, PROGRAM, Humans, COHORT, Articles and Commentaries, Ethambutol, media_common, business.industry, multidrug resistant, Extensively drug-resistant tuberculosis, Odds ratio, Pyrazinamide, Middle Aged, medicine.disease, Multiple drug resistance, meta-analysis, Infectious Diseases, Treatment Outcome, tuberculosis, Female, business, FOLLOW-UP, medicine.drug
Abstract

Background. Individualized treatment for multidrug-resistant (MDR) tuberculosis and extensively drug-resistant (XDR) tuberculosis depends upon reliable and valid drug susceptibility testing (DST) for pyrazinamide, ethambutol, and second-line tuberculosis drugs. However, the reliability of these tests is uncertain, due to unresolved methodological issues. We estimated the association of DST results for pyrazinamide, ethambutol, and second-line drugs with treatment outcomes in patients with MDR tuberculosis and XDR tuberculosis.Methods. We conducted an analysis of individual patient data assembled from 31 previously published cohort studies of patients with MDR and XDR tuberculosis. We used data on patients' clinical characteristics including DST results, treatment received, outcomes, and laboratory methods in each center.Results. DST methods and treatment regimens used in different centers varied considerably. Among 8955 analyzed patients, in vitro susceptibility to individual drugs was consistently and significantly associated with higher odds of treatment success (compared with resistance to the drug), if that drug was used in the treatment regimen. Various adjusted and sensitivity analyses suggest that this was not explained by confounding. The adjusted odds of treatment success for ethambutol, pyrazinamide, and the group 4 drugs ranged from 1.7 to 2.3, whereas for second-line injectables and fluoroquinolones, odds ranged from 2.4 to 4.6.Conclusions. DST for ethambutol, pyrazinamide, and second-line tuberculosis drugs appears to provide clinically useful information to guide selection of treatment regimens for MDR and XDR tuberculosis.

Published
2014

39. Treatment Outcomes of Patients With Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis According to Drug Susceptibility Testing to First- and Second-line Drugs: An Individual Patient Data Meta-analysis

Author

Bastos, Mayara L., Hussain, Hamidah, Weyer, Karin, Garcia-Garcia, Lourdes, Leimane, Vaira, Leung, Chi Chiu, Narita, Masahiro, Penã, Jose M., Ponce-de-Leon, Alfredo, Seung, Kwonjune J., Shean, Karen, Sifuentes-Osornio, José, Van der Walt, Martie, Van der Werf, Tjip S., Yew, Wing Wai, Menzies, Dick, Ahuja, S., Ashkin, D., Avendaño, M., Banerjee, R., Bauer, M., Becerra, M., Benedetti, A., Burgos, M., Centis, R., Chan, E.D., Chiang, C.Y., Cobelens, F., Cox, H., D'Ambrosio, L., de Lange, W.C.M., DeRiemer, K., Enarson, D., Falzon, D., Flanagan, K., Flood, J., Gandhi, N., Garcia-Garcia, L., Granich, R.M., Hollm-Delgado, M.G., Holtz, T.H., Hopewell, P., Iseman, M., Jarlsberg, L.G., Keshavjee, S., Kim, H.R., Koh, W.J., Lancaster, J., Lange, C., Leimane, V., Leung, C.C., Li, J., Menzies, D., Migliori, G.B., Mitnick, C.M., Narita, M., Nathanson, E., Odendaal, R., O'Riordan, P., Pai, M., Palmero, D., Park, S.K., Pasvol, G., Pena, J., Pérez-Guzmán, C., Ponce-de-Leon, A., Quelapio, M.I.D., Quy, H.T., Riekstina, V., Robert, J., Royce, S., Salim, M., Schaaf, H.S., Seung, K.J., Shah, L., Shean, K., Shim, T.S., Shin, S.S., Shiraishi, Y., Sifuentes-Osornio, J., Sotgiu, G., Strand, M.J., Sung, S.W., Tabarsi, P., Tupasi, T.E., Vargas, M.H., van Altena, R., van der Walt, M., van der Werf, T.S., Viiklepp, P., Westenhouse, J., Yew, W.W., and Yim, J.J.

Abstract

The clinical validity of drug susceptibility testing (DST) for pyrazinamide, ethambutol, and second-line antituberculosis drugs is uncertain. In an individual patient data meta-analysis of 8955 patients with confirmed multidrug-resistant tuberculosis, DST results for these drugs were associated with treatment outcomes

Published
2017

40. Culture Conversion at 6 Months in Patients Receiving Delamanid-containing Regimens for the Treatment of Multidrug-resistant Tuberculosis.

Author

Seung, Kwonjune J, Khan, Palwasha, Franke, Molly F, Ahmed, Saman, Aiylchiev, Stalbek, Alam, Manzur, Putri, Fauziah Asnely, Bastard, Mathieu, Docteur, Wisny, Gottlieb, Gary, Hewison, Catherine, Islam, Shirajul, Khachatryan, Naira, Kotrikadze, Tinatin, Khan, Uzma, Kumsa, Andargachew, Lecca, Leonid, Tassew, Yoseph Melaku, Melikyan, Nara, and Naing, Ye Yint

Subjects
*ANTITUBERCULAR agents, *IMIDAZOLES, *MICROBIAL sensitivity tests, *SPUTUM, *TIME
Abstract

Delamanid should be effective against highly resistant strains of Mycobacterium tuberculosis , but uptake has been slow globally. In the endTB (expand new drug markets for TB) Observational Study, which enrolled a large, heterogeneous cohorts of patients receiving delamanid as part of a multidrug regimen, 80% of participants experienced sputum culture conversion within 6 months. Clinical Trials Registration. NCT02754765. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

41. The growing problem of multidrug-resistant tuberculosis in North Korea

Author

Seung, Kwonjune J. and Linton, Stephen W.

Subjects
Drug resistance in microorganisms -- Research, Tuberculosis -- Physiological aspects, Prevalence studies (Epidemiology) -- Research, Biological sciences
Abstract

Tuberculosis in North Korea Tuberculosis (TB) has long been one of the most serious public health problems in North Korea (Democratic People's Republic of Korea). The estimated TB incidence of [...]

Published
2013
Full Text
View/download PDF

42. Efficacy and Safety of High-Dose Rifampin in Pulmonary Tuberculosis. A Randomized Controlled Trial

Author

Velásquez, Gustavo E., primary, Brooks, Meredith B., additional, Coit, Julia M., additional, Pertinez, Henry, additional, Vargas Vásquez, Dante, additional, Sánchez Garavito, Epifanio, additional, Calderón, Roger I., additional, Jiménez, Judith, additional, Tintaya, Karen, additional, Peloquin, Charles A., additional, Osso, Elna, additional, Tierney, Dylan B., additional, Seung, Kwonjune J., additional, Lecca, Leonid, additional, Davies, Geraint R., additional, and Mitnick, Carole D., additional

Published
2018
Full Text
View/download PDF

43. Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis

Author

Ahmad, Nafees, primary, Ahuja, Shama D, additional, Akkerman, Onno W, additional, Alffenaar, Jan-Willem C, additional, Anderson, Laura F, additional, Baghaei, Parvaneh, additional, Bang, Didi, additional, Barry, Pennan M, additional, Bastos, Mayara L, additional, Behera, Digamber, additional, Benedetti, Andrea, additional, Bisson, Gregory P, additional, Boeree, Martin J, additional, Bonnet, Maryline, additional, Brode, Sarah K, additional, Brust, James C M, additional, Cai, Ying, additional, Caumes, Eric, additional, Cegielski, J Peter, additional, Centis, Rosella, additional, Chan, Pei-Chun, additional, Chan, Edward D, additional, Chang, Kwok-Chiu, additional, Charles, Macarthur, additional, Cirule, Andra, additional, Dalcolmo, Margareth Pretti, additional, D'Ambrosio, Lia, additional, de Vries, Gerard, additional, Dheda, Keertan, additional, Esmail, Aliasgar, additional, Flood, Jennifer, additional, Fox, Gregory J, additional, Fréchet-Jachym, Mathilde, additional, Fregona, Geisa, additional, Gayoso, Regina, additional, Gegia, Medea, additional, Gler, Maria Tarcela, additional, Gu, Sue, additional, Guglielmetti, Lorenzo, additional, Holtz, Timothy H, additional, Hughes, Jennifer, additional, Isaakidis, Petros, additional, Jarlsberg, Leah, additional, Kempker, Russell R, additional, Keshavjee, Salmaan, additional, Khan, Faiz Ahmad, additional, Kipiani, Maia, additional, Koenig, Serena P, additional, Koh, Won-Jung, additional, Kritski, Afranio, additional, Kuksa, Liga, additional, Kvasnovsky, Charlotte L, additional, Kwak, Nakwon, additional, Lan, Zhiyi, additional, Lange, Christoph, additional, Laniado-Laborín, Rafael, additional, Lee, Myungsun, additional, Leimane, Vaira, additional, Leung, Chi-Chiu, additional, Leung, Eric Chung-Ching, additional, Li, Pei Zhi, additional, Lowenthal, Phil, additional, Maciel, Ethel L, additional, Marks, Suzanne M, additional, Mase, Sundari, additional, Mbuagbaw, Lawrence, additional, Migliori, Giovanni B, additional, Milanov, Vladimir, additional, Miller, Ann C, additional, Mitnick, Carole D, additional, Modongo, Chawangwa, additional, Mohr, Erika, additional, Monedero, Ignacio, additional, Nahid, Payam, additional, Ndjeka, Norbert, additional, O'Donnell, Max R, additional, Padayatchi, Nesri, additional, Palmero, Domingo, additional, Pape, Jean William, additional, Podewils, Laura J, additional, Reynolds, Ian, additional, Riekstina, Vija, additional, Robert, Jérôme, additional, Rodriguez, Maria, additional, Seaworth, Barbara, additional, Seung, Kwonjune J, additional, Schnippel, Kathryn, additional, Shim, Tae Sun, additional, Singla, Rupak, additional, Smith, Sarah E, additional, Sotgiu, Giovanni, additional, Sukhbaatar, Ganzaya, additional, Tabarsi, Payam, additional, Tiberi, Simon, additional, Trajman, Anete, additional, Trieu, Lisa, additional, Udwadia, Zarir F, additional, van der Werf, Tjip S, additional, Veziris, Nicolas, additional, Viiklepp, Piret, additional, Vilbrun, Stalz Charles, additional, Walsh, Kathleen, additional, Westenhouse, Janice, additional, Yew, Wing-Wai, additional, Yim, Jae-Joon, additional, Zetola, Nicola M, additional, Zignol, Matteo, additional, and Menzies, Dick, additional

Published
2018
Full Text
View/download PDF

46. Aggressive Regimens for Multidrug-Resistant Tuberculosis Decrease All-Cause Mortality

Author

Mitnick, Carole D., primary, Franke, Molly F., additional, Rich, Michael L., additional, Alcantara Viru, Felix A., additional, Appleton, Sasha C., additional, Atwood, Sidney S., additional, Bayona, Jaime N., additional, Bonilla, Cesar A., additional, Chalco, Katiuska, additional, Fraser, Hamish S. F., additional, Furin, Jennifer J., additional, Guerra, Dalia, additional, Hurtado, Rocio M., additional, Joseph, Keith, additional, Llaro, Karim, additional, Mestanza, Lorena, additional, Mukherjee, Joia S., additional, Muñoz, Maribel, additional, Palacios, Eda, additional, Sanchez, Epifanio, additional, Seung, Kwonjune J., additional, Shin, Sonya S., additional, Sloutsky, Alexander, additional, Tolman, Arielle W., additional, and Becerra, Mercedes C., additional

Published
2013
Full Text
View/download PDF

48. Correction: Multidrug Resistant Pulmonary Tuberculosis Treatment Regimens and Patient Outcomes: An Individual Patient Data Meta-analysis of 9,153 Patients

Author

Ahuja, Shama D., primary, Ashkin, David, additional, Avendano, Monika, additional, Banerjee, Rita, additional, Bauer, Melissa, additional, Bayona, Jamie N., additional, Becerra, Mercedes C., additional, Benedetti, Andrea, additional, Burgos, Marcos, additional, Centis, Rosella, additional, Chan, Eward D., additional, Chiang, Chen-Yuan, additional, Cox, Helen, additional, D'Ambrosio, Lia, additional, DeRiemer, Kathy, additional, Dung, Nguyen Huy, additional, Enarson, Donald, additional, Falzon, Dennis, additional, Flanagan, Katherine, additional, Flood, Jennifer, additional, Garcia-Garcia, Maria L., additional, Gandhi, Neel, additional, Granich, Reuben M., additional, Hollm-Delgado, Maria G., additional, Holtz, Timothy H., additional, Iseman, Michael D., additional, Jarlsberg, Leah G., additional, Keshavjee, Salmaan, additional, Kim, Hye-Ryoun, additional, Koh, Won-Jung, additional, Lancaster, Joey, additional, Lange, Christophe, additional, de Lange, Wiel C. M., additional, Leimane, Vaira, additional, Leung, Chi Chiu, additional, Li, Jiehui, additional, Menzies, Dick, additional, Migliori, Giovanni B., additional, Mishustin, Sergey P., additional, Mitnick, Carole D., additional, Narita, Masa, additional, O'Riordan, Philly, additional, Pai, Madhukar, additional, Palmero, Domingo, additional, Park, Seung-kyu, additional, Pasvol, Geoffrey, additional, Peña, Jose, additional, Pérez-Guzmán, Carlos, additional, Quelapio, Maria I. D., additional, Ponce-de-Leon, Alfredo, additional, Riekstina, Vija, additional, Robert, Jerome, additional, Royce, Sarah, additional, Schaaf, H. Simon, additional, Seung, Kwonjune J., additional, Shah, Lena, additional, Shim, Tae Sun, additional, Shin, Sonya S., additional, Shiraishi, Yuji, additional, Sifuentes-Osornio, José, additional, Sotgiu, Giovanni, additional, Strand, Matthew J., additional, Tabarsi, Payam, additional, Tupasi, Thelma E., additional, van Altena, Robert, additional, Van der Walt, Martie, additional, Van der Werf, Tjip S., additional, Vargas, Mario H., additional, Viiklepp, Pirett, additional, Westenhouse, Janice, additional, Yew, Wing Wai, additional, Yim, Jae-Joon, additional, and Ahuja, Shama D., additional

Published
2012
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results